637015-79-3Relevant academic research and scientific papers
New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold
Pajk, Stane,?ivec, Matej,?ink, Roman,Sosi?, Izidor,Neu, Margarete,Chung, Chun-Wa,Martínez-Hoyos, María,Pérez-Herrán, Esther,álvarez-Gómez, Daniel,álvarez-Ruíz, Emilio,Mendoza-Losana, Alfonso,Castro-Pichel, Julia,Barros, David,Ballell-Pages, Lluís,Young, Robert J.,Convery, Maire A.,Encinas, Lourdes,Gobec, Stanislav
, p. 252 - 257 (2016)
Tetrahydropyran derivative 1 was discovered in a high-throughput screening campaign to find new inhibitors of mycobacterial InhA. Following initial in-vitro profiling, a structure-activity relationship study was initiated and a focused library of analogs was synthesized and evaluated. This yielded compound 42 with improved antimycobacterial activity and low cytotoxicity. Additionally, the crystal structure of InhA in complex with inhibitor 1 was resolved, to reveal the binding mode and provide hints for further optimization.
MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER
-
Paragraph 0072; 0087, (2016/07/27)
Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.
AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS
-
Page 64, (2008/06/13)
The present invention is related to azole derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such azole derivatives. Said azole derivatives are modulators of the protein kinase signalling pathways, particularly the one involving c-Jun N-terminal kinase and/or Glycogen Kinase Synthase 3. The present invention is furthermore related to novel azole derivatives as well as to methods of their preparation. X is O, S or NR0, with R0 being H or an unsubstituted or substituted C1 -C6 alkyl; A is 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl group.
